The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors
暂无分享,去创建一个
Jonathan A. Javitch | Ravi Kumar Verma | Ara M. Abramyan | Mayako Michino | R. Benjamin Free | David R. Sibley | Jonathan Robert Lane | Lei Shi | D. Sibley | J. R. Lane | Lei Shi | J. Javitch | M. Michino | R. Verma | R. Free
[1] B. Brooks,et al. Constant pressure molecular dynamics simulation: The Langevin piston method , 1995 .
[2] M. Connor,et al. A6V polymorphism of the human μ‐opioid receptor decreases signalling of morphine and endogenous opioids in vitro , 2015, British journal of pharmacology.
[3] Roman A. Laskowski,et al. LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery , 2011, J. Chem. Inf. Model..
[4] Jonathan A. Javitch,et al. Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.
[5] Shailesh N Mistry,et al. Structure-activity study of N-((trans)-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652), a bitopic ligand that acts as a negative allosteric modulator of the dopamine D2 receptor. , 2015, Journal of medicinal chemistry.
[6] D. Sibley,et al. Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R). , 2017, Journal of medicinal chemistry.
[7] Mayako Michino,et al. Structural basis for Na(+)-sensitivity in dopamine D2 and D3 receptors. , 2015, Chemical communications.
[8] F. Noé,et al. Efficient Bayesian estimation of Markov model transition matrices with given stationary distribution. , 2013, The Journal of chemical physics.
[9] Francesca Zazzeroni,et al. The Tetrahydroisoquinoline Derivative SB269,652 Is an Allosteric Antagonist at Dopamine D3 and D2 Receptors , 2010, Molecular Pharmacology.
[10] Vijay S Pande,et al. Improvements in Markov State Model Construction Reveal Many Non-Native Interactions in the Folding of NTL9. , 2013, Journal of chemical theory and computation.
[11] Ara M. Abramyan,et al. The Isomeric Preference of an Atypical Dopamine Transporter Inhibitor Contributes to Its Selection of the Transporter Conformation. , 2017, ACS chemical neuroscience.
[12] Frank Noé,et al. Markov models of molecular kinetics: generation and validation. , 2011, The Journal of chemical physics.
[13] John D. Scott,et al. Endogenous N-terminal Domain Cleavage Modulates α1D-Adrenergic Receptor Pharmacodynamics* , 2016, The Journal of Biological Chemistry.
[14] S. R. Nash,et al. Dopamine receptors: from structure to function. , 1998, Physiological reviews.
[15] J. Deschamps,et al. Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D3 Receptor. , 2017, Journal of medicinal chemistry.
[16] Marcus Weber,et al. Fuzzy spectral clustering by PCCA+: application to Markov state models and data classification , 2013, Advances in Data Analysis and Classification.
[17] Benoît Roux,et al. AUTOMATED FORCE FIELD PARAMETERIZATION FOR NON-POLARIZABLE AND POLARIZABLE ATOMIC MODELS BASED ON AB INITIO TARGET DATA. , 2013, Journal of chemical theory and computation.
[18] Ralf C. Kling,et al. Molecular determinants of biased agonism at the dopamine D₂ receptor. , 2015, Journal of medicinal chemistry.
[19] V. Pande,et al. Error analysis and efficient sampling in Markovian state models for molecular dynamics. , 2005, The Journal of chemical physics.
[20] Frank Noé,et al. An Introduction to Markov State Models and Their Application to Long Timescale Molecular Simulation , 2014, Advances in Experimental Medicine and Biology.
[21] Lei Shi,et al. A Single Glycine in Extracellular Loop 1 Is the Critical Determinant for Pharmacological Specificity of Dopamine D2 and D3 Receptors , 2013, Molecular Pharmacology.
[22] Alexander D. MacKerell,et al. Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. , 2010, The journal of physical chemistry. B.
[23] Toni Giorgino,et al. Identification of slow molecular order parameters for Markov model construction. , 2013, The Journal of chemical physics.
[24] Alexander D. MacKerell,et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.
[25] Arthur Christopoulos,et al. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders , 2009, Nature Reviews Drug Discovery.
[26] Marta Filizola,et al. Dopamine D2 receptors form higher order oligomers at physiological expression levels , 2008, The EMBO journal.
[27] Lei Shi,et al. Novel Bivalent Ligands Based on the Sumanirole Pharmacophore Reveal Dopamine D2 Receptor (D2R) Biased Agonism. , 2017, Journal of medicinal chemistry.
[28] Helgi B. Schiöth,et al. Structural diversity of G protein-coupled receptors and significance for drug discovery , 2008, Nature Reviews Drug Discovery.
[29] R. Stevens,et al. Structure-function of the G protein-coupled receptor superfamily. , 2013, Annual review of pharmacology and toxicology.
[30] Lei Shi,et al. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. , 2012, Journal of medicinal chemistry.
[31] R. Friesner,et al. Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.
[32] Harel Weinstein,et al. Computational approaches to detect allosteric pathways in transmembrane molecular machines. , 2016, Biochimica et biophysica acta.
[33] P. Sexton,et al. A new mechanism of allostery in a G protein-coupled receptor dimer , 2014, Nature chemical biology.
[34] A. Newman,et al. Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders , 2010, Annals of the New York Academy of Sciences.
[35] Arthur Christopoulos,et al. Bridging the gap: bitopic ligands of G-protein-coupled receptors. , 2013, Trends in pharmacological sciences.
[36] Alexander D. MacKerell,et al. Extending the treatment of backbone energetics in protein force fields: Limitations of gas‐phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations , 2004, J. Comput. Chem..
[37] R. McGibbon,et al. Variational cross-validation of slow dynamical modes in molecular kinetics. , 2014, The Journal of chemical physics.
[38] Alexander D. MacKerell,et al. CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..
[39] V. Setola,et al. Role of the N-Terminal Region in G Protein–Coupled Receptor Functions: Negative Modulation Revealed by 5-HT2B Receptor Polymorphisms , 2013, Molecular Pharmacology.
[40] Shailesh N Mistry,et al. Discovery of a Novel Class of Negative Allosteric Modulator of the Dopamine D2 Receptor Through Fragmentation of a Bitopic Ligand. , 2015, Journal of medicinal chemistry.
[41] M. Connor,et al. Buprenorphine signalling is compromised at the N40D polymorphism of the human μ opioid receptor in vitro , 2014, British journal of pharmacology.
[42] Frank Noé,et al. PyEMMA 2: A Software Package for Estimation, Validation, and Analysis of Markov Models. , 2015, Journal of chemical theory and computation.
[43] J. Ballesteros,et al. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .
[44] Frank Noé,et al. Variational Approach to Molecular Kinetics. , 2014, Journal of chemical theory and computation.
[45] Noel M. Paul,et al. Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists , 2015, European Neuropsychopharmacology.
[46] Frank Noé,et al. A Variational Approach to Modeling Slow Processes in Stochastic Dynamical Systems , 2012, Multiscale Model. Simul..
[47] Lei Shi,et al. What Can Crystal Structures of Aminergic Receptors Tell Us about Designing Subtype-Selective Ligands? , 2015, Pharmacological Reviews.
[48] J. Beaulieu,et al. Dopamine receptors – IUPHAR Review 13 , 2015, British journal of pharmacology.
[49] R. Gainetdinov,et al. The Physiology, Signaling, and Pharmacology of Dopamine Receptors , 2011, Pharmacological Reviews.
[50] Alexander D. MacKerell,et al. Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles. , 2012, Journal of chemical theory and computation.